Slide 1: Investor Presentation Y2022 results
INVESTOR PRESENTATION Y2022 results WARSAW // 27.04.2023
Slide 2: Disclaimer
Disclaimer. Neither this presentation (the “Presentation”, references to which shall be deemed to include any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further enquiries) nor any copy of it nor the information contained herein
Slide 3: Pharma Financials
PHARMA FINANCIALS
Slide 4: Segment dynamics - FY 2021/2022
Segment dynamics - FY 2021/2022 Well balanced business model with growing R&D costs INNOVATIVE PRODUCTS (R&D) TOTAL BRANDED GENERICS R&D Revenues . Revenues Revenues 194,6 199,1 162,6 172,6 32,0 26,5 FY 2022 FY 2021 FY 2022 FY 2021 FY 2022 FY 2021 Expenses Expenses Expenses 118,2 115,7 113,1 231,4 2
Slide 5: Group and Segment P&L Details
Group and Segment P&L Details. Branded generics segment Innovation segment Total PLN million FY 2022 FY 2021 FY 2022 FY 2021 FY 2022 FY 2021 Revenues from sales of medicines 159,3 168,8 0,0 0,0 159,3 168,8 Other revenues 0,7 3,0 0,0 0,0 0,7 3,0 Revenues from grants 0,0 0,0 32,0 26,5 32,0 26,5 Revenu
Slide 6: Balance sheet
Balance sheet. PLN mln 2022-12-31 2021-12-31 ASSETS 642,7 707,1 A. Increase in property, plant and equipment as at 31Dec22 compared to Non-current assets 404,9 428,4 Property, plant and equipment A 306,8 303,7 31Dec21 is related to intense CAPEX that the Company has been Right-of-use assets A 34,8 2
Slide 7: Branded Generics
PHARMA BRANDED GENERICS
Slide 8: Revenues 2020-2022
Revenues 2020-2022 Total revenues comparable to the previous years prove the validity of our business assumptions. +10,9 +5,5 (MLN PLN) 200 +36 +4,7 199,1 194,6 - 20,9 159,9 -1,5 100 0 2020 Domestic Export Grants 2021 Domestic Export Grants 2022 sales sales Celon Pharma – 2022 results 8
Slide 9: Improved sales dynamics in Poland in 2022
Improved sales dynamics in Poland in 2022 Trend to be continued in 2023 based on the existing portfolio and the introduction of new products 2022/2021 Salmex Ketrel Valzek Donepex +3% + 14% + 2% + 13% Y/Y 14 000 12 470 11 870 12 000 11 819 11 486 11 320 909 11 228 11 226 769 732 10 902 10 714 752 56
Slide 10: Export - temporary slowdown in sales dynamics in 2022
Export - temporary slowdown in sales dynamics in 2022, should be improved in the next quarters of 2023 due to both, orders from previously stocked export markets, as well as launches of sales on new markets, already covered by license agreements. 2020 8,5 mln USD 2021 19,5 mln USD *without profit sh
Slide 11: Innovative Business
PHARMA INNOVATIVE BUSINESS
Slide 12: Neuropsychiatry: Diversified platforms drive strong pipeline
Diversified platforms drives strong pipeline CLINICAL DEVELOPMENT INDICATION MOLECULAR TARGET RESEARCH PRE-CLINICAL DEVELOPMENT PHASE I PHASE II Solid tumours FGFR Inhibitor CPL’110 Solid tumours/ haematological cancers MER Inhibitor ONCOLOGY Solid tumours Bispecific antibody targeting immune system
Slide 13: News flow & key milestones 2023
News flow & key milestones 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2023 CPL’280 end of Phase 2 in diabates CPL’36 end of Phase 2 in both indications CPL’116 end of Phase 2 in RA CPL’280 start of Phase 2b in diabetes CPL’280start Phase 2 in diabetes neuropathy CPL’110 end of Phase 1/1b CPL’116 in IPF start C
Slide 14: Partnering strategy 2023/2024
Partnering strategy 2023/2024 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 FALKIERI CPL’ 280 CPL’280 CPL’36 CPL’110 CPL’116 CPL’110 Celon Pharma – 2022 results 14
Slide 15: QA
QA
Slide 16: Thank you
Thank you